biontech
Bioengineers have successfully developed sensors as fine as spider's silk. Researchers at the University of Cambridge in the UK say the extremely light sensors could be used to monitor human health, such as heartbeats, or to detect detailed changes in the environment. The sensors are 50 times thinner than human hair and so lightweight that the scientists were able to print the fibre directly onto a dandelion without it collapsing. In a recently published study, the sensor was tested to pick up signals such as heartbeats in the same way as an electrocardiogram (ECG). The research team says the ...
Euronews (English)
BioNTech had a strong quarter despite slowing COVID sales.A robust pipeline makes it a takeover target for larger pharma companies.A share repurchase program should help support price action in 2023.5 stocks we like better than BioNTechBioNTech (NASDAQ:BNTX) got a substantial boost from the pandemic and its mRNA vaccine, developed with Pfizer (NYSE:PFE). The stock has seen a substantial correction since then due to slowing COVID sales, but the bottom is in. Q4 2022 hedge fund letters, conferences and more Find A Qualified Financial AdvisorEach advisor has been vetted by SmartAsset and is held ...
ValueWalk
Washington (AFP) - Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world. The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease. "Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement....
AFP
Pfizer and BioNTech will start a clinical trial for an Omicron-specific vaccine. The study will include three cohorts of healthy adult participants ranging from ages 18 to 55. The first group will include those who had two doses of the Pfizer vaccine at least 90 to 180 days ahead of the study. They will receive either one or two doses of the Omicron vaccine. The second group will be made of participants who have had three doses of the Pfizer vaccine, also at least 90-180 days prior. This group will be given one dose of the Omicron-specific vaccine. Finally, the third group will include partici...
uPolitics.com
Vaccine manufacturers Pfizer and BioNTech have announced that two doses of their Covid-19 vaccine provide significant protection against the rapidly spreading omicron variant and that a supplemental booster shot was found to “neutralize” the mutated pathogen, based on blood tests that they conducted from individuals who had received second and third injections. “Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers,” the pharmaceutica...
uPolitics.com
The Food and Drug Administration approved COVID-19 vaccine booster shots for people with weakened immune systems, according to CNBC. With this move, the organization intends to protect the most vulnerable population from the delta variant, now prevalent in the country. Q2 2021 hedge fund letters, conferences and more Covid Booster AuthorizedActing FDA Commissioner Dr. Janet Woodcock said in a statement: “Today’s action allows doctors to boost immunity in certain immunocompromised individuals who need extra protection from COVID-19.” The measure will mean that organ transplant recipients, and H...
ValueWalk
Washington (AFP) - Pfizer and BioNTech announced Thursday they would seek regulatory authorization for a third dose of their Covid-19 vaccine. It comes after initial data from an ongoing trial showed a third shot pushed antibody levels five to 10 times higher against the original coronavirus strain and the Beta variant, first found in South Africa, compared to the first two doses alone, according to a statement. "The companies expect to publish more definitive data soon as well as in a peer-reviewed journal and plan to submit the data to the FDA (Food and Drug Administration), EMA (European Me...
AFP
Pfizer CEO Albert Bourla said that recipients of his company’s COVID-19 vaccination, as well as those of similar make-up like the Moderna vaccine, will “likely” require a third dose for increased immunity against the virus and its variants. Bourla also indicated people may need annual doses of the vaccine, similar to a flu shot. “A likely scenario is that there will be likely a need for a third dose, somewhere between six and 12 months and then from there, there will be an annual re-vaccination, but all of that needs to be confirmed. And again, the variants will play a key role,” Bourla said i...
uPolitics.com
Paris (AFP) - With a strategic alliance, 24-hour production and a bit of luck, Pfizer and BioNTech were able to roll out their Covid vaccine at a brisk pace and relatively free of controversy. US pharmaceutical giant Pfizer and BioNTech, a smaller German biotech firm, joined forces on April 9, 2020, as the world reeled from the pandemic, with deaths soaring and nations under lockdown. The companies set an ambitious goal: Producing hundreds of millions of jabs in 2021 -- an incredibly short timeline when vaccines usually take years to develop and secure regulatory approval. Seven months later, ...
AFP
An increasing number of studies shows that the new South African strain of COVID can infect people who have already had the disease, and that vaccines have little effect on it. It is possible that the entire current vaccination program could be rendered ineffective by this strain, that the vaccines will have to be improved, and the vaccination will have to be restarted from scratch. However, is the panic really justified? Q4 2020 hedge fund letters, conferences and more If we disregard the immediate emotional reaction and consider the statistics that we currently have, we can realise that the ...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら